论文部分内容阅读
目的检测人表皮生长因子-2(C-erb B-2)、突变型p53、Ki-67在早期子宫内膜癌组织中的表达及其与临床病理参数的关系。方法采用免疫组织化学法检测C-erb B-2、突变型p53、Ki-67蛋白在增生期子宫内膜15例(增生期子宫内膜组),非典型增生子宫内膜15例(非典型增生子宫内膜组),子宫内膜癌60例(子宫内膜癌组)中的表达情况。结果C-erb B-2、突变型p53、Ki-67在子宫内膜癌组中的阳性表达率分别为33.33%、35.00%、75.00%。子宫内膜癌组中Cerb B-2阳性表达率明显高于增生期子宫内膜组及非典型增生子宫内膜组;突变型p53、Ki-67的阳性表达率明显高于增生期子宫内膜组及非典型增生子宫内膜组,差异有统计学意义(χ~2值分别为7.292,23.627,P<0.05),增生期子宫内膜组与非典型增生子宫内膜组间的差异无统计学意义(χ~2=4.647,P>0.05)。C-erb B-2在子宫内膜癌组中阳性表达随手术病理分期、组织学分级、肌层浸润深度的增加阳性表达逐渐升高,但差异均无统计学意义(χ~2=0.313,P>0.05)。突变型p53在子宫内膜癌组Ⅰ期与Ⅱ期之间差异无统计学意义(χ~2=0.659,P>0.05);而在G1与G3两者比较差异有统计学意义(χ~2=12.290,P=0.001);突变型P53随肌层浸润深度增加阳性表达逐渐升高,但差异无统计学意义(χ~2=3.956,P>0.05)。Ki-67随肌层浸润深度增加阳性表达逐渐升高,差异有统计学意义(χ~2=19.622,P<0.05)。子宫内膜癌组织中C-erb B-2、突变型p53与Ki-67阳性表达呈正相关(r=0.589,P=0.000;r=0.780,P=0.000),而C-erb B-2与突变型p53在子宫内膜癌中的阳性表达无相关性(r=0.148,P=0.258)。结论联合检测C-erb B-2、突变型p53、Ki-67对评价子宫内膜癌的发生、发展、恶性程度及预后更具有临床价值。
Objective To detect the expression of human epidermal growth factor-2 (C-erb B-2), mutant p53 and Ki-67 in early endometrial carcinoma and its relationship with clinicopathological parameters. Methods Immunohistochemistry was used to detect the expression of C-erb B-2, p53 and Ki-67 in proliferative endometrium, 15 cases of proliferative endometrium, 15 cases of atypical hyperplasia endometrium Hyperplasia endometrial group), endometrial cancer in 60 cases (endometrial cancer group) in the expression. Results The positive rates of C-erb B-2, mutant p53 and Ki-67 in endometrial carcinoma were 33.33%, 35.00% and 75.00% respectively. The positive rate of Cerb B-2 in endometrial carcinoma group was significantly higher than that in proliferative endometrium group and atypical hyperplasia endometrium group. The positive rates of mutant p53 and Ki-67 were significantly higher than those in proliferative endometrium Group and atypical hyperplasia endometrium group, the difference was statistically significant (χ ~ 2 values were 7.292,23.627, P <0.05), no difference between proliferative endometrium group and atypical hyperplasia endometrium group Significance (χ ~ 2 = 4.647, P> 0.05). The positive expression of C-erb B-2 in endometrial carcinoma group was gradually increased with the pathological stage, histological grade and depth of myometrial invasion, but the difference was not statistically significant (χ ~ 2 = 0.313, P> 0.05). Mutant p53 showed no significant difference between stage Ⅰ and stage Ⅱ in endometrial carcinoma (χ ~ 2 = 0.659, P> 0.05), but there was a significant difference between G1 and G3 (χ ~ 2 = 12.290, P = 0.001). The positive expression of mutant P53 increased with the depth of myometrial invasion (χ ~ 2 = 3.956, P> 0.05). The positive expression of Ki-67 increased with the depth of myometrial invasion (χ ~ 2 = 19.622, P <0.05). The positive expression of C-erb B-2, mutant p53 and Ki-67 in endometrial carcinoma were positively correlated (r = 0.589, P = 0.000; r = 0.780, P = 0.000) Mutant p53 expression in endometrial cancer had no correlation (r = 0.148, P = 0.258). Conclusions The combined detection of C-erb B-2, mutant p53 and Ki-67 has clinical value in the evaluation of the occurrence, development, malignancy and prognosis of endometrial carcinoma.